Loading…
Pasithea Therapeutics Corp. is projected to rise to $0.4821 by 2027, a +8% move from its current price of $0.4466. KTTA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.4341 | $0.4467 | $0.4596 | +0.02% |
| Aug 6 | $0.4291 | $0.4468 | $0.4652 | +0.05% |
| Aug 7 | $0.4254 | $0.4469 | $0.4695 | +0.07% |
| Aug 8 | $0.4222 | $0.447 | $0.4732 | +0.09% |
| Aug 9 | $0.4195 | $0.4471 | $0.4765 | +0.11% |
| Aug 10 | $0.417 | $0.4472 | $0.4796 | +0.14% |
| Aug 11 | $0.4148 | $0.4473 | $0.4824 | +0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4148 | $0.4473 | $0.4824 | +0.16% |
| Week 2 | $0.4027 | $0.448 | $0.4985 | +0.32% |
| Week 3 | $0.3937 | $0.4487 | $0.5114 | +0.47% |
| Week 4 | $0.3865 | $0.4494 | $0.5226 | +0.63% |
| Week 5 | $0.3802 | $0.4501 | $0.5329 | +0.79% |
| Week 6 | $0.3748 | $0.4508 | $0.5424 | +0.95% |
| Week 7 | $0.3698 | $0.4516 | $0.5513 | +1.11% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase (MEK) inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp.
was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Pasithea Therapeutics Corp. (KTTA) trades with a current price of $0.444 and has a market cap of $14.84M, ranking 4691. The price outlook, based on the provided forecast, shows a flat to modestly rising path in 2026, with a 2026 min of $0.444, a 2026 avg of $0.444, and a max of $0.6113, and a 0% ROI.
Beyond 2026, the forecast depicts a gradual rise in average prices through the late 2020s and into the 2030s, culminating in higher long-term targets (2033-2050) with increasingly positive ROIs, including a 187.8% ROI by 2050 and a max price of $2.39 in the same horizon.
A major floor 17.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.6% away) — a key level to hold.
The nearest ceiling, 27.2% above — a clean break opens room to run.
A major ceiling 90.3% above — clearing it would confirm fresh momentum.
Key KTTA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KTTA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.4508 | Sell | $0.4539 | Sell |
| MA 10 | $0.4577 | Sell | $0.4592 | Sell |
| MA 20 | $0.4739 | Sell | $0.478 | Sell |
| MA 50 | $0.5504 | Sell | $0.5461 | Sell |
| MA 100 | $0.6593 | Sell | $0.6307 | Sell |
| MA 200 | $0.767 | Sell | $0.8045 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.76 | Neutral |
| Stoch RSI (14) | 94.65 | Sell |
| CCI (20) | -44.36 | Neutral |
| Williams %R (14) | -57.89 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -3.77 | Sell |
| Bollinger %B (20,2) | 0.36 | Neutral |
| Stochastic %K (14) | 42.11 | Neutral |
| TRIX (15) | -0.90 | Sell |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 45.77 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 0.45 | Sell |
| ADX (14) | 29.72 | Sell |
| ATR (14) | 0.01 | Info |
The 30-day technical picture is neutral. RSI(14) sits at 30, while the 50-day simple moving average is $0.5553 and the 200-day simple moving average is $0.7684, suggesting price action is moving below near-term and longer-term averages. The stock currently finds support at $0.444 and faces resistance at $0.568.
The 30-day range runs from $0.369 to $0.5342, indicating a narrow recent trading band. Annualized volatility is high at 50%, underscoring notable price swings within the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.444 | $0.4466 | $0.6151 | 0% | Neutral | |
| $0.383 | $0.4821 | $0.6424 | +8% | Neutral | |
| $0.3713 | $0.4815 | $0.6672 | +8% | Neutral | |
| $0.3587 | $0.4766 | $0.6808 | +7% | Neutral | |
| $0.32 | $0.4345 | $0.6366 | -3% | Neutral | |
| $0.3428 | $0.4748 | $0.7113 | +6% | Neutral | |
| $0.3655 | $0.5156 | $0.7879 | +15% | Neutral | |
| $0.3865 | $0.5547 | $0.8629 | +24% | Bullish | |
| $0.4281 | $0.6244 | $0.9875 | +40% | Bullish | |
| $0.4203 | $0.6227 | $1.00 | +39% | Bullish | |
| $0.502 | $0.7987 | $1.37 | +79% | Bullish | |
| $0.7151 | $1.29 | $2.42 | +188% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.444 | $0.4466 | $0.5543 | +0.00% |
| September 2026 | $0.3901 | $0.4618 | $0.5623 | +3.40% |
| October 2026 | $0.3823 | $0.4559 | $0.5615 | -1.28% |
| November 2026 | $0.3938 | $0.4724 | $0.5871 | +3.62% |
| December 2026 | $0.407 | $0.4908 | $0.6151 | +3.91% |
Click any year to see its month-by-month KTTA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect KTTA to range from $0.444 to $0.6151 through 2026. The $0.4466 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The KTTA price prediction for 2027 points to an average of $0.4821 (low $0.383, high $0.6424) — a potential gain of +8% on today's $0.4466. Price action looks broadly range-bound.
In 2028, KTTA is projected to trade between $0.3713 and $0.6672, averaging $0.4815 — a potential gain of +8% from today's $0.4466. That is 0% versus the projected 2027 average. A consolidation phase looks the most probable path here.
Pasithea Therapeutics Corp.'s 2029 outlook centres on $0.4766, within a $0.3587 to $0.6808 range. That is -1% versus the projected 2028 average. That marks a +7% change versus current levels. Price action looks broadly range-bound.
By 2030, KTTA could reach as high as $0.6366, with a base case around $0.4345 and support toward $0.32 — roughly -3% from $0.4466. A consolidation phase looks the most probable path here.
Expect KTTA to range from $0.3428 to $0.7113 through 2031. The $0.4748 average target implies a +6% move from current prices. That is up +9% on the projected 2030 average. Price action looks broadly range-bound.
The KTTA price prediction for 2032 points to an average of $0.5156 (low $0.3655, high $0.7879) — a potential gain of +15% on today's $0.4466. A consolidation phase looks the most probable path here.
In 2033, KTTA is projected to trade between $0.3865 and $0.8629, averaging $0.5547 — a potential gain of +24% from today's $0.4466. That is up +8% on the projected 2032 average. Momentum favours further upside here.
Pasithea Therapeutics Corp.'s 2034 outlook centres on $0.6244, within a $0.4281 to $0.9875 range. That is up +13% on the projected 2033 average. That marks a +40% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, KTTA could reach as high as $1.00, with a base case around $0.6227 and support toward $0.4203 — roughly +39% from $0.4466. Momentum favours further upside here.
Expect KTTA to range from $0.502 to $1.37 through 2040. The $0.7987 average target implies a +79% move from current prices. That is up +28% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The KTTA price prediction for 2050 points to an average of $1.29 (low $0.7151, high $2.42) — a potential gain of +188% on today's $0.4466. Momentum favours further upside here.
Investing $1,000 in KTTA today (≈ 2,239.14017 KTTA) could be worth
$2,881.14
+$1,881.14 (+188%) by 2050 · US Dollar
Based on the average projected KTTA price of $1.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KTTAwould be worth at today's price.
$1,000 invested in KTTA on Jul 31, 2025 (≈ 1,379.310299 KTTA) would be worth
$616
-$384 (-38.4%) today · 0.62× · US Dollar
Based on a KTTA entry price of $0.725 vs. today's $0.4466.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.455 | $981.54 | -1.8% |
| 1 month ago | $0.567 | $787.65 | -21.2% |
| 3 months ago | $0.841 | $531.03 | -46.9% |
| 6 months ago | $0.845 | $528.52 | -47.1% |
| 1 year ago | $0.725 | $616 | -38.4% |
| All time (4.9y) ago | $71.2 | $6.27 | -99.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KTTA forecast.
Our base-case forecast reaches $0.89 around 2050.
Implied market cap at $0.89: $29.74M
Over the multi-year horizon, the forecast turns increasingly bullish after 2032. In 2030 the average price is projected at $0.4321 with a minimum of $0.3191, a maximum of $0.6312, and a -2.7% ROI. The 2031 forecast shows an average of $0.4748 and a 6.9% ROI, followed by 2032 with an average of $0.5126 and a 15.4% ROI.
The outlook becomes bullish from 2033 onward, with average prices of $0.55 (ROI 23.9%), $0.6236 (ROI 40.5%), and $0.6181 (ROI 39.2%) in 2033–2035. The trajectory continues to 2040 with an average of $0.7974 and a 79.6% ROI, and to 2050 with an average of $1.28 and a 187.8% ROI, reaching a max of $2.39. These figures imply meaningful upside potential in the long run, but also acknowledge that earlier years show mixed performance and that actual results can differ from projections.
Tap a question to reveal the answer.
Avg price $0.4321; min $0.3191; max $0.6312; ROI -2.7%.
The 2026 forecast shows min $0.444, avg $0.444, max $0.6113 with 0% ROI, indicating no gain that year. Later years turn bullish, with average prices rising to $0.55–$1.28 by 2040–2050 and ROIs up to 187.8%.
Yes. The long-term forecast shows an average of $1.28 by 2050 and a max price of $2.39, indicating potential to exceed $1.00, though outcomes are not guaranteed.
Sentiment: NEUTRAL. RSI(14): 30. SMA(50): $0.5553. SMA(200): $0.7684. Support: $0.444. Resistance: $0.568. 30-day range: $0.369–$0.5342. Annualized volatility: 50%.
Current price: $0.444. Market cap: $14.84M. Rank: 4691.
Pasithea Therapeutics Corp. Community Discussion
0Share your Pasithea Therapeutics Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.